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Brain arteriovenous malformations (bAVMs) are abnormal shunts that bypass the capil-
lary bed and directly divert blood from the arterial to the venous circulation, without 
exchanging nutrients or dissipating the arterial blood pressure. They are thought to 
be congenital vascular lesions that occur during the late stages of fetal development, 
however the exact pathogenesis has not been elucidated yet.1 History of hemorrhage, 
small AVM size, high arterial feeding blood pressure, and deep venous drainage are the 
main risk factors that increase the likelihood of AVM rupture. According to the American 
Stroke Association, 1 in 200-500 people have an AVM, while 25% of AVM patients experi-
ence seizures and 50% of patients suffer intracranial hemorrhage (ICH) at some point 
in their lives.2 Also, 5-15% of AVM patients experience severe headaches because of the 
increased intracranial pressure and a similar percentage of patients exhibit neurological 
deficits.1 With the advent of noninvasive imaging, AVMs are being detected at an early, 
unruptured stage, but the optimal course of action for preventing future complica-
tions still remains uncertain. The ARUBA trial strove to determine whether medical 
management or interventional therapy has a better long-term outcome for patients 
with unruptured AVMs. While it provides important data, limitations in its study design 
raise doubts concerning the generalizability of its findings.
The study planned to include 800 patients who were to be followed for a minimum 
of five and a maximum of seven years.3 They were randomly assigned to one of two 
groups, the interventional therapy and medical management group. Patients in the 
medical management group received only pharmacological therapy for the medical 
symptoms that they experienced (unless they developed hemorrhage or infarction, 
in which case they were switched into the other group). Patients in the interventional 
therapy group received endovascular surgery, microsurgery, or radiosurgery, with or 
without pharmacological therapy depending on their concurrent medical conditions. 
The primary hypothesis was that medical management is more effective in the treat-
ment of patients with unruptured bAVMs, the primary endpoint was death or stroke, 
the secondary endpoint was the quality of life, while the functional outcome status was 
measured using the Rankin scale.3
Previous studies had shown that early interventional treatment in patients with ruptured 
bAVMs is necessary and patients did not have major future clinical problems.3 Inter-
ventional therapy includes endovascular surgery, which aims to occlude the nidus by 
delivering liquid embolics or embolic coils via a catheter, microsurgical resection of the 
AVM, or radiosurgery that induces a vascular injury response resulting in AVM obliteration 
within 1 or 2 years.1 A multimodal therapy that involves more than one of these inter-
ventional procedures can also be performed on certain patients. Furthermore, medical 
management was shown to be very effective in treating unruptured bAVMs as indicated 
by the very low rate of future hemorrhage. Yet, based on data from the Columbia Univer-
sity Medical Center, interventional treatment of ruptured AVMs had a significantly greater 
likelihood of hemorrhage and/or clinical impairment (Rankin score ≥2) than medical 
management of unruptured AVMs. It is 
thus imperative to compare the effec-
tiveness of the two methods of treatment 
only on patients with unruptured bAVMs, 
since patients who present with an ICH 
have an already much higher risk of 
experiencing a subsequent ICH (hazard 
ratio of 3.6).4 The ARUBA trial is the first 
study comparing medical management to 
surgical care on patients with unruptured 
bAVMs and a Rankin score less than two.3
RESULTS
The trial started on April 4, 2007 and 
ended on April 15, 2013 after following 223 
patients for 33 months on average. Both 
groups had very similar demographics, 
clinical symptoms, lesion characteristics 
and modified Rankin scores, with the 
exception of the interventional therapy 
group having a slightly higher propor-
tion of small bAVMs (less than 3 cm).4 
The study ended earlier than planned 
because it was determined that patients 
who received interventional therapy had 
a 3-fold increase in their risk of death or 
stroke than those who only received phar-
macological treatment4. More specifically, 
10.1% of patients in the medical manage-
ment group and 30.7% of patients in the 
interventional therapy group reached 
the primary endpoint, stroke or death 
from any cause during the study.5 The 
primary endpoint incidence rate in the 
interventional therapy group was found to 
be very similar to the complication rates 
of the various invasive procedures when 
treating bled and unbled brain AVMs: 29% 
for surgery, 25% for embolization, and 
13% for radiotherapy. In contrast, medical 
management patients had a 2.2% sponta-
neous rupture rate per year.4
The participants of the ARUBA trial will 
continue to be monitored for at least five 
more years in order to assess whether 
the differences observed in the clinical 
outcome and the Rankin scores will 
remain the same over time.
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the generalizability of the trial findings 
questionable. First, there is concern that 
Mohr et al. introduced selection bias in 
the study by studying only relatively mild 
cases of bAVMs, because including only 
bAVMs without any previous complica-
tions is not reflective of the majority 
of the cases seen in the hospital. Only 
13% (226 out of 1740) of the patients 
screened were selected, but the reasons 
for excluding the rest were not explicitly 
stated.6 If the actual risk of spontaneous 
rupture is higher, then conservative 
medical management may not be suffi-
cient. Additionally, the effectiveness of 
each interventional method varies drasti-
cally based on the bAVM morphology.8,9,10 
Mohr et al. did not provide enough infor-
mation concerning the success rate of 
each procedure used to treat the different 
bAVM types. More details are needed 
about the embolic material used in the 
embolization procedures, the number 
and outcome of patients with total 
versus near-total occlusion, and the use 
of gamma knife versus linear accelerator 
in radiotherapy.7 Lastly, many consider 
microsurgical resection of bAVMs to be 
more effective than embolization and 
radiosurgery in obliterating the nidus, yet 
it was used on very few patients. It was the 
only treatment used in 5% of the patients 
and used in combination with another 
procedure in 13% of the patients, but the 
reasons behind the preferential use of the 
other two methods over microsurgical 
resection were not explained.6,7 
Due to these limitations in the ARUBA 
trial, it is questionable whether we can 
group all of the interventional methods 
together when assessing their effective-
ness in curing bAVMs in comparison to 
medical management. More research 
needs to be conducted on the long-term 
clinical outcome of the two methods of 
treatment, taking into consideration the 
increased rupture risk with aging and the 
varying complication rate of the inter-
ventional methods based on the bAVM 
morphology.
DISCUSSION
Brain AVMs can be detected early on 
while they are unruptured and mostly 
asymptomatic, but the ideal treatment 
is still uncertain. The ARUBA trial argues 
that the best treatment for these patients 
is solely medical management, using 
anticonvulsants if the patient has seizures, 
and analgesics if the patient experiences 
headaches. However, the ARUBA trial has 
received plenty of criticism concerning 
its study design and the credibility of its 
findings. 
The trial states that 30.7% of patients 
in the interventional treatment group 
reached the primary endpoint, but the 
actual symptoms experienced by the 
patients are not specified. The primary 
endpoint, stroke, is very broadly defined, 
including seizure, a new neurological 
deficit, or headache that results from 
ischemia or hemorrhage.7 There is an 
obvious difference in the severity of each 
of these clinical presentations, but the 
researchers did not identify the likelihood 
of each symptom based on which inter-
ventional treatment the patient received.7 
Moreover, even though the spontaneous 
rupture rate per year for patients who 
undergo medical management is 2.2%, 
the rate increases with increasing age 
and patients continue to be at high risk 
throughout their lives. The complication 
rates of the various interventional treat-
ments are indeed higher, however, the 
purpose of interventional therapy is to 
obliterate the bAVM so that patients can 
avoid increased risk and be worry-free in 
the future. Therefore, monitoring patients 
for only 33 months is inadequate; patients 
need to be monitored for a few decades 
in order to assess the risk of hemor-
rhage throughout their lifespan, as this 
is imperative information for making the 
right decision by both the doctor and the 
patient.6 
Furthermore, the vast heterogeneity 
in the bAVM morphology and in the 
selection of the interventional treat-
ment that the patients received deems 
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